Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.93
$0.126.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 12.85M | 20.76M | 30.40M | 37.33M | 44.06M |
| Total Receivables | 21.40K | 55.00K | 97.00K | 224.90K | 193.20K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 3.43M | 2.98M | 2.04M | 2.03M | 2.70M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 16.30M | 23.79M | 32.54M | 39.58M | 46.95M |
|
|
|||||
| Total Current Assets | 16.30M | 23.79M | 32.54M | 39.58M | 46.95M |
| Net Property, Plant & Equipment | 21.37M | 19.92M | 20.75M | 21.79M | 22.63M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 449.80K | 482.10K | 514.40K | 521.70K | 554.00K |
| Total Assets | 38.12M | 44.20M | 53.80M | 61.89M | 71.37M |
|
|
|||||
| Total Accounts Payable | 2.52M | 1.69M | 1.30M | 1.17M | 1.24M |
| Total Accrued Expenses | 6.06M | 5.47M | 6.88M | 5.05M | 5.17M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.08M | 811.80K | 524.70K | 1.21M | 1.51M |
| Total Finance Division Other Current Liabilities | -- | -- | 114.70K | 114.70K | 377.80K |
| Total Other Current Liabilities | -- | -- | 114.70K | 114.70K | 377.80K |
| Total Current Liabilities | 9.65M | 7.98M | 8.82M | 7.55M | 8.31M |
|
|
|||||
| Total Current Liabilities | 9.65M | 7.98M | 8.82M | 7.55M | 8.31M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 5.71M | 3.86M | 4.00M | 4.13M | 3.94M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 1.35M | 6.39M | 4.08M | 4.09M | 6.31M |
| Total Liabilities | 16.71M | 18.23M | 16.89M | 15.77M | 18.55M |
|
|
|||||
| Common Stock & APIC | 156.41M | 155.80M | 155.15M | 154.10M | 153.50M |
| Retained Earnings | -129.37M | -124.17M | -112.77M | -102.42M | -95.09M |
| Treasury Stock & Other | -5.63M | -5.66M | -5.47M | -5.55M | -5.58M |
| Total Common Equity | 21.41M | 25.97M | 36.90M | 46.12M | 52.82M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|||||
| Total Common Equity | 21.41M | 25.97M | 36.90M | 46.12M | 52.82M |
| Total Preferred Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 21.41M | 25.97M | 36.90M | 46.12M | 52.82M |
|
|
|||||